KIORA PHARMACEUTICALS INC — Director's Dealing 2021

Apr 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2021-04-19

Reporting Person: Shapiro Aron (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-19	Stock Option (right to buy)	$4.40	A	4000	Acquired	2031-04-19	Common Stock (4000)	Direct

Footnotes

F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 19, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.